Synthetic Biologics Statistics Share Statistics Synthetic Biologics has 15.84M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 15.84M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 15.54M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 392.02K, so 0% of the outstanding
shares have been sold short.
Short Interest 392.02K Short % of Shares Out n/a Short % of Float 2.49% Short Ratio (days to cover) 7.4
Valuation Ratios The PE ratio is -0.05 and the forward
PE ratio is null.
Synthetic Biologics's PEG ratio is
0.
PE Ratio -0.05 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.07 P/FCF Ratio -0.08 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Synthetic Biologics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.15,
with a Debt / Equity ratio of 0.08.
Current Ratio 2.15 Quick Ratio 2.15 Debt / Equity 0.08 Debt / EBITDA -0.06 Debt / FCF -0.09 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.6M Employee Count 16 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.39, so Synthetic Biologics's
price volatility has been higher than the market average.
Beta 1.39 52-Week Price Change n/a 50-Day Moving Average 1.32 200-Day Moving Average n/a Relative Strength Index (RSI) 33.94 Average Volume (20 Days) 160,387
Income Statement
Revenue n/a Gross Profit n/a Operating Income -26.35M Net Income -25.65M EBITDA -26.35M EBIT n/a Earnings Per Share (EPS) -19.03
Full Income Statement Balance Sheet The company has 11.61M in cash and 1.47M in
debt, giving a net cash position of 10.14M.
Cash & Cash Equivalents 11.61M Total Debt 1.47M Net Cash 10.14M Retained Earnings -334.97M Total Assets 35.83M Working Capital 2.35M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -16.94M
and capital expenditures -1K, giving a free cash flow of -16.94M.
Operating Cash Flow -16.94M Capital Expenditures -1K Free Cash Flow -16.94M FCF Per Share -12.56
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields SYN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for SYN.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 25, 2022. It was a
backward
split with a ratio of 1:10.
Last Split Date Jul 25, 2022 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -16.77 Piotroski F-Score 3
